Evidence map›Paper›PMID 42182619›Full record

ArticleDose-response : a publication of International Hormesis Society

Efficacy and Safety of Fibroblast Activation Protein Targeted Radioligand Therapy for Advanced Solid Tumour: A Systematic Review and Meta-Analysis.

Xiaoli Zhang, Jianpeng Cao, Xue Jiang, Yuxiao Xia, Ying Huang, Qian Liu, Lina Liu, Dongkun Xu, Hongjie Wu, Wenling Tu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dose-response : a publication of International Hormesis Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaoli ZhangDepartment of Nuclear Medicine, China National Nuclear Corporation 416 Hospital, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P. R. China.
Jianpeng CaoDepartment of Nuclear Medicine, China National Nuclear Corporation 416 Hospital, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P. R. China.
Xue JiangDepartment of Nuclear Medicine, China National Nuclear Corporation 416 Hospital, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P. R. China.
Yuxiao XiaDepartment of Nuclear Medicine, China National Nuclear Corporation 416 Hospital, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P. R. China.
Ying HuangDepartment of Nuclear Medicine, China National Nuclear Corporation 416 Hospital, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P. R. China.
Qian LiuDepartment of Nuclear Medicine, China National Nuclear Corporation 416 Hospital, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P. R. China.
Lina LiuDepartment of Nuclear Medicine, China National Nuclear Corporation 416 Hospital, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P. R. China.
Dongkun XuDepartment of Nuclear Medicine, China National Nuclear Corporation 416 Hospital, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P. R. China.
Hongjie WuDepartment of Nuclear Medicine, China National Nuclear Corporation 416 Hospital, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P. R. China.
Wenling TuDepartment of Nuclear Medicine, China National Nuclear Corporation 416 Hospital, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P. R. China.ORCID https://orcid.org/0000-0001-8100-8511
Yuhong ShiDepartment of Nuclear Medicine, China National Nuclear Corporation 416 Hospital, The Second Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, P. R. China.ORCID https://orcid.org/0000-0003-0475-5649

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Fibroblast activation protein (FAP) is a promising cancer theranostic target. While FAP-based diagnostics have proven highly accurate, the efficacy and safety of FAP-targeted radioligand therapy (FAP-RLT) for advanced, treatment-refractory solid tumours are poorly characterized. Methods: We performed a systematic review and meta-analysis of clinical trials reporting therapeutic outcomes and adverse events of FAP-RLT up to 25 January 2025 (PubMed, ClinicalTrials.gov, Cochrane Library, Web of Science/MEDLINE). Primary endpoints were objective response rate (ORR), disease control rate (DCR), and incidence of grade ≥ 3 adverse events. Results: The objective response rate of FAP-RLT treatment was 11.7% (95%CI: 3.2%-23.2%; Conclusion: FAP-RLT has demonstrated significant disease control in multiple advanced solid tumours while maintaining a favourable safety profile. These findings can contribute to clinical treatment expectations and support informed policy decision-making in oncology.

Indexed as

adverse eventsefficacyfibroblast activation protein (FAP)radioligand therapy (RLT)radiotheranostics

Identifiers

PMID42182619
PMCPMC13195222

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.